–Reduction in total cholesterol, LDL, IDL, and TG (PAP inhibition) levels in plasma.–Reduction in fasting plasma glucose levels.–Increased HDL levels.–Reduction in inflammation and liver fibrosis through PARP inhibition.–Increased PKB phosphorylation. The gene discussed is AKT1; the disease is Hepatic fibrosis.